logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Gastrointestinal, Pancreatic and Liver Disease

Results

Drugs

June 2020

Etrolizumab for treating moderately to severely active ulcerative colitis in adults

Etrolizumab is a new monoclonal antibody (an immune protein) delivered by subcutaneous injection. The treatment works by targeting molecules called integrins to control the immune response and prevent the accumulation of immune molecules, which cause inflammation in individuals with a form of ulcerative colitis where inflammation is not mediated by a signalling protein called tumour necrosis factors (TNF) alpha (‘non-TNF-α’) and who are therefore intolerant to TNF blockers. This represents a new target group as current therapies focus mainly on anti-TNF inflammation. In one study, etrolizumab showed a greater reduction of intestinal lymphocyte infiltration in comparison to standard treatment.

Drugs

May 2020

Maralixibat for Progressive Familial Intrahepatic Cholestasis Type 2

Maralixibat is an orally administered drug that is expected to reduce the level of bile acids. It is expected to interfere with the process by which most bile acids in the intestines are recovered and delivered back to the liver through the blood, thereby reducing the liver damage and itching seen in patients with PFIC2. If licensed, maralixibat will provide the first disease-modifying treatment option for patients with PFIC2, a disease of unmet clinical need.

Drugs

November 2019

Filgotinib for moderately to severely active ulcerative colitis

Filgotinib is in clinical development for the treatment of patients with moderately to severely active ulcerative colitis. Ulcerative colitis is a type of inflammatory bowel disease that causes inflammation and ulcers in the bowel and rectum which can cause diarrhoea, abdominal pain and faecal urgency or incontinence. The symptoms of ulcerative colitis often follow a pattern of relapse and remission where they have periods of none or mild symptoms followed by periods of increased symptoms flare-up (‘active’). There are no curative therapies for ulcerative colitis and current treatment aims to relieve symptoms during a flare-up and maintain remission by preventing symptoms from returning.

Drugs

July 2019

Imlifidase for kidney transplantation in highly sensitised patients with chronic kidney disease

Imlifidase is in clinical development for enabling kidney transplantation in highly sensitised patients with chronic kidney disease (CKD). CKD is a long-term irreversible condition where the kidneys do not work as well as they should. Kidney transplantation is considered to be treatment of choice for patients with end stage kidney disease. Many patients on the waiting list for organ transplantation carry antibodies to human leukocyte antigen (HLA), which is known as being ‘sensitised.’ Patients who are highly sensitised may find it difficult getting a donor and may not be able to receive a transplant due to increased risk of kidney rejection.

Drugs

June 2019

OTL-200 for Metachromatic Leukodystrophy

OTL-200 is a gene therapy that involves extraction of certain stem cells from a patient’s bone marrow or blood. These stem cells are genetically modified and then returned to the patient by intravenous infusion to deliver the corrected version of the gene to the cells in charge of creating key proteins. The corrected cells then produce the protein that was missing or defective prior to treatment, aiming to halt disease progression or modify its natural course. If licensed, OTL-200 will offer a potentially curative treatment option for patients with MLD, who currently have no effective therapies available.

Drugs

May 2019

Obeticholic acid for non-alcoholic steatohepatitis and fibrosis

Obeticholic acid as a tablet is in clinical development for the treatment of advanced liver fibrosis due to non-alcoholic steatohepatitis (NASH). Non-alcoholic fatty liver disease (NAFLD) is the general term for conditions in which an excessive amount of fat is stored in the liver, but where this excess is not caused by heavy alcohol use. A build-up of fat alone is called simple fatty liver (steatosis). NASH occurs when the presence of fat leads to liver cell damage and inflammation (hepatitis). Over time, liver cell damage and inflammation due to NASH can cause scarring (fibrosis) of the liver which may increase until advanced. Once there is advanced fibrosis due to NASH, there is a higher risk of progression to cirrhosis and its complications such as liver failure, liver cancer, and death. Although simple fatty liver, NASH, and advanced fibrosis due to NASH are distinct types of NAFLD in terms of the risk to health they pose, they are considered stages of the same disease through which people will progress if lifestyle interventions are not effective.

Drugs

July 2018

Ustekinumab for Moderately to Severely Active Ulcerative Colitis

Ustekinumab is a drug which is given as an injection and works by blocking the molecules that are involved in the inflammation which occurs in UC. Ustekinumab is already licenced for use in people with Crohn’s disease, which is another type of IBD. If ustekinumab is licenced this would provide another treatment option for people with moderate to severe active UC.

Drugs

May 2018

Selonsertib for Non-alcoholic Steatohepatitis (NASH)

Selonsertib is an investigational oral small molecule inhibitor of ASK1, a protein that mediates inflammation, apoptosis (cell death) and fibrosis in settings of oxidative stress. Oxidative stress can be increased in many pathological conditions including liver diseases such as NASH. NASH currently has no effective treatment apart from lifestyle interventions. If licensed, selonsertib will offer a new treatment option for NASH as no effective pharmacological therapies currently exist.

Drugs

February 2018

Timolumab for Primary Sclerosing Cholangitis

Timolumab is currently being developed to treat PSC. Timolumab is given by injection into the vein which blocks a molecule called VAP-1 from working. VAP-1 helps immune cells enter areas of inflammation (such as the bile ducts in PSC) where they can further contribute to inflammation. By blocking this process, timolumab has the potential to prevent some of the inflammation in PSC and slow the progress of the disease.

Drugs

February 2018

Tenapanor for Irritable Bowel Syndrome with Constipation

Irritable bowel syndrome with constipation (IBS-C) is a common condition that affects the digestive system (the gut). Symptoms may include stomach cramps, bloating and constipation. The exact cause is unknown, and IBS-C is often a lifelong condition. While there is no cure, dietary changes and the use of medication can often help control symptoms. IBS-C …

Get Alerts